## CLAIMS

1. A composition comprising
a mixture M comprising or, alternatively, consisting of:
- a bacterial strain identified as *Bifidobacterium bifidum* MIMBb23sg and deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under deposit number DSM 32708 on 4 December 2017 by Sofar S.p.A; and
- at least one bacterial strain selected from the group A comprising or, alternatively, consisting of:
- a bacterial strain identified as *Bifidobacterium breve* BbIBS01 and deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under deposit number DSM 33231 on 31 July 2019 by Sofar S.p.A.,
- a bacterial strain identified as *Bifidobacterium breve* BbIBS02 and deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under deposit number DSM 33232 on 31 July 2019 by Sofar S.p.A.,
- a bacterial strain identified as *Bifidobacterium animalis subsp. lactis* BlIBS01 and deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under deposit number DSM 33233 on 31 July 2019 by Sofar S.p.A.,
- a bacterial strain identified as *Lactobacillus plantarum* LpIBS01 and deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under deposit number DSM 33234 on 31 July 2019 by Sofar S.p.A.,
and mixtures thereof;
and, optionally, said composition comprises at least one food or pharmaceutical grade additive and/or excipient.

2. The composition according to claim 1, wherein said mixture M comprises or, alternatively consists of bacterial strains:
- *Bifidobacterium bifidum* MIMBb23sg (o BbfIBS01) DSM 32708,
- *Bifidobacterium breve* BbIBS01 DSM 33231,
- *Bifidobacterium breve* BbIBS02 DSM 33232,
- *Bifidobacterium animalis subsp. lactis* BlIBS01 DSM 33233, and
- *Lactobacillus plantarum* LpIBS01 DSM 33234.

3. The composition according to claim 1 or 2, wherein said mixture M further comprises at least one further bacterial strain selected from the group B comprising or, alternatively, consisting of:
- a bacterial strain identified as *Lactobacillus casei* DG® and deposited at the National Collection of

Cultures of Microorganisms of the Pasteur Institute in Paris under accession number CNCM I-1572 on 05 May 1995 by SOFAR S.p.A., and

- a bacterial strain identified as *Lactobacillus paracasei* LPC-S01™ and deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under accession number DSM 26760 on 15 May 2017 by SOFAR S.p.A.

4. The composition according to claim 3, wherein said mixture M comprises or, alternatively consists of bacterial strains:

- *Bifidobacterium bifidum* MIMBb23sg (o BbfIBS01) DSM 32708,
- *Bifidobacterium breve* BbIBS01 DSM 33231,
- *Bifidobacterium breve* BbIBS02 DSM 33232,
- *Bifidobacterium animalis subsp. lactis* BlIBS01 DSM 33233,
- *Lactobacillus plantarum* LpIBS01 DSM 33234, and
- *Lactobacillus casei* DG® CNCM I-1572.

5. The composition according to claim 3, wherein said mixture M comprises or, alternatively consists of bacterial strains:

- *Bifidobacterium bifidum* MIMBb23sg (o BbfIBS01) DSM 32708,
- *Bifidobacterium breve* BbIBS01 DSM 33231,
- *Bifidobacterium breve* BbIBS02 DSM 33232,
- *Bifidobacterium animalis subsp. lactis* BlIBS01 DSM 33233,
- *Lactobacillus plantarum* LpIBS01 DSM 33234, and
- *Lactobacillus paracasei* LPC-S01™ DSM 26760.

6. The composition according to any one of claims 1 to 5, wherein said composition is formulated for oral, sublingual or buccal, transmucosal, topical rectal, topical cutaneous or topical vaginal use; preferably said composition is formulated for oral use.

7. The composition according to any one of claims 1 to 6 for use as a medicament.

8. The composition according to any one of claims 1 a 6 for use in a method for the preventive and/or curative treatment of functional gastrointestinal diseases, disorders and/or symptoms.

9. The composition according to claim 8, wherein said composition is for use in a method for the preventive and/or curative treatment of functional gastrointestinal diseases, disorders and/or symptoms

selected from the group comprising or, alternatively, consisting of: irritable bowel syndrome (IBS), dyspepsia, pyrosis, oesophagus, stomach and duodenum disorders, small intestinal bacterial overgrowth (SIBO), gastrointestinal disorders with sub-inflammatory conditions.

10. The composition according to claim 9, wherein said composition is for use in a method for the preventive or curative treatment of the irritable bowel syndrome (IBS) with constipation or irritable bowel syndrome (IBS) with diarrhoea or irritable bowel syndrome (IBS) with alternating constipation and diarrhoea or unclassified irritable bowel syndrome (IBS).

11. The composition according to any one of claims 1 to 6 for use in a method for the preventive and/or curative treatment of inflammatory gastrointestinal diseases, disorders and/or symptoms.

12. The composition according to claim 11, wherein said composition is for use in a method for the preventive or curative treatment of inflammatory gastrointestinal disorders selected from the group comprising or, alternatively, consisting of: chronic inflammatory bowel diseases (IBD), Crohn's disease, ulcerative colitis, microscopic colitis, diverticular disease, diverticulitis, Helicobacter pylori, peptic or gastric ulcer, and duodenal ulcer; preferably selected from chronic inflammatory bowel diseases (IBD), Crohn's disease, ulcerative colitis, microscopic colitis, diverticular disease, and diverticulitis.